bladder urothelial carcinoma
Conditions
Interventions
Case series:trimodal therapy
Sponsors
Department of Urology, Chongqing University Cancer Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 78 Years
Inclusion criteria
Inclusion criteria: (1) Aged 20 to 78 years; (2) ECOG 0-2; (3) Bladder urothelial carcinoma diagnosed by the pathological histology ,and needed the radical resection; (4) Patients with strong retain bladder will and good compliance; (5) Tumor can be treated by excision of transurethral resection or bladder part; (6) Normal bladder function; (7) Laboratory examination must be in accordance with the following indicators: Hb > 90 g/L, WBC > 3.5 * 10^9/L, platelets > 90 * 10^9/L; Transaminase and total bilirubin is less than 1.5 UNL; Creatinine < 144 umol/L; (8) Voluntary participation, the participants himself or his legal representative sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Pathology results for the carcinoma was not the urinary tract, such as squamous cell carcinoma, adenocarcinoma and small cell carcinoma and sarcoma, etc; (2) CT found positive pelvic lymph nodes (multiple, length to diameter is greater than 1 cm); (3) Confirmed by pathology or researchers identified with lymph node metastasis; (4) CT or MRI imaging found distant metastases (visceral metastasis, bone metastasis, etc.); (5) Activity or have symptoms of viral hepatitis or other chronic liver diseases; (6) allergies by paclitaxel, gemcitabine,cisplatin,and other platinum-based preparations; (7) Pregnancy and lactation; (8) Once had treatment by other chemotherapy or radiation therapy; (9) Chickenpox, herpes zoster, gout and high uric acid hematic disease, peripheral neuritis; (10) The clinical significance of heart disease, including: in the past six months have myocardial infarction, or arterial thrombosis; Severe or unstable angina; New York heart association class III or IV heart disease; Atrial fibrillation or other need treatment of arrhythmia; (11) Has a history of kidney disease, hematopoietic function is not complete, the auditory nerve dysfunction; (12) With other malignant tumor in the past five years; (13) The other condition that is not suitable to participate in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response rate of disease after 2 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| FACT-P;ECOG;Disease progression-free surial;OS; | — |
Countries
China
Contacts
Public ContactNan Liu
Department of Urology, Chongqing University Cancer Hospital
Outcome results
None listed